Momenta Pharmaceuticals Inc (MNTA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Momenta Pharmaceuticals Inc (MNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10018
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Momenta Pharmaceuticals Inc (Momenta) is a biotechnology company which specializes in the structural analysis, characterization, and design of complex pharmaceuticals. The company’s products include Glatopa; and Enoxaparin Sodium Injection. Its pipeline portfolio encompasses candidates to substitute Copaxone 40 mg/mL, Humira, and Orencia; an anti-FcRn antibody; selective immune-modulator of Fc receptors; hyper-sialylated IVIg as well as investigational candidate for the treatment of pancreatic cancer. The company utilizes its technology for developing generic versions of biosimilars, complex drugs, and potentially interchangeable biologics, and also in the discovery and development of therapeutics for various cancers and autoimmune indications. Momenta is headquartered in Cambridge, Massachusetts, the US.

Momenta Pharmaceuticals Inc (MNTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 11
Partnerships 12
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 12
Licensing Agreements 13
AbbVie Enters into Licensing Agreement with Momenta Pharma 13
CSL Enters into Licensing Agreement with Momenta Pharma 14
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 16
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Equity Offering 19
Momenta Pharma Plans to Raise USD65 Million in Public Offering of Shares 19
Momenta Pharma Raises USD158 Million Public Offering of Shares 20
Momenta Pharma Raises USD75 Million in Public Offering of Shares 22
Momenta Pharmaceuticals Inc – Key Competitors 23
Momenta Pharmaceuticals Inc – Key Employees 24
Momenta Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 07, 2018: Momenta Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 26
Aug 09, 2018: Momenta Pharmaceuticals announces second quarter 2018 financial results 28
May 08, 2018: Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 30
Feb 21, 2018: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update 33
Nov 01, 2017: Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 36
Aug 02, 2017: Momenta Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 39
May 02, 2017: Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results 42
Feb 21, 2017: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results 45
Corporate Communications 48
Oct 02, 2017: Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer 48
Jun 01, 2017: Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer 49
Legal and Regulatory 50
Mar 21, 2018: Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals and Sandoz 50
Government and Public Interest 51
Jan 06, 2017: Momenta Provides Year-End 2016 Corporate Update 51
Product News 53
05/17/2018: Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity 53
01/03/2018: Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept) 54
Clinical Trials 55
Jan 05, 2018: Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Momenta Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 11
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 12
AbbVie Enters into Licensing Agreement with Momenta Pharma 13
CSL Enters into Licensing Agreement with Momenta Pharma 14
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 16
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Momenta Pharma Plans to Raise USD65 Million in Public Offering of Shares 19
Momenta Pharma Raises USD158 Million Public Offering of Shares 20
Momenta Pharma Raises USD75 Million in Public Offering of Shares 22
Momenta Pharmaceuticals Inc, Key Competitors 23
Momenta Pharmaceuticals Inc, Key Employees 24
Momenta Pharmaceuticals Inc, Subsidiaries 25

List of Figures
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Momenta Pharmaceuticals Inc (MNTA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Inform Genomics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Inform Genomics Inc (Inform Genomics) manufactures and markets genomic-based personalized medicine products for cancer and supportive care. The company’s onpart is a medicinal product, which is used for the treatment of decisions in patients, who receive chemotherapy for colorectal, breast, …
  • Institut Pasteur-製薬・医療分野:企業M&A・提携分析
    Summary Institut Pasteur is a non-profit foundation that provides research, health services and education. The institute offers research in the areas of biology, genomes and genetics, immunology, infection and epidemiology, microbiology, neuroscience, parasitology and mycology, structural biology an …
  • Centrais Eletricas do Para SA (CELP5):電力:M&Aディール及び事業提携情報
    Summary Centrais Eletricas do Para SA (CELPA), a subsidiary of Equatorial Energia SA is an electric utility that supplies and distributes power and electricity. The utility offers services such as electric metering, online bill payment, surge protection, outage reporting, energy saving tips, rebates …
  • Australian Mines Limited:企業の戦略・SWOT・財務分析
    Australian Mines Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Gruma, S.A.B. de C.V.:企業の戦略・SWOT・財務情報
    Gruma, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Gruma, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Janssen Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Janssen Pharmaceuticals Inc (Janssen), a subsidiary of Johnson & Johnson is a pharmaceutical company that develops drugs. The company offers medicines for an array of health conditions in therapeutic areas of attention deficit hyperactivity disorder, general medicine, mental health, neurolog …
  • Stanwell Corporation Ltd:企業の戦略的SWOT分析
    Stanwell Corporation Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Athena Investments AS (ATHENA):電力:M&Aディール及び事業提携情報
    Summary Athena Investments AS(Athena), Previously known as Greentech Energy System A/S is an energy company which operates renewable energy plants. It generates electricity from wind and solar sources. Through long-term power purchase agreements, the company sells electricity. Athena expands its ass …
  • Eramet:企業の戦略・SWOT・財務情報
    Eramet - Strategy, SWOT and Corporate Finance Report Summary Eramet - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • BioLight Israeli Life Sciences Ltd (BOLT):医療機器:M&Aディール及び事業提携情報
    Summary BioLight Israeli Life Sciences Ltd (Bio-Light), formerly Bio Light Israeli Life Sciences Investments Ltd is an ophthalmic company that discovers, develops and commercializes products and product candidates for various ophthalmic conditions. The company invests in managing and commercializing …
  • Trinity Biotech Plc (TRIB):製品パイプライン分析
    Summary Trinity Biotech Plc (Trinity Biotech) is a medical equipment company which develops, acquires, manufactures and distributes diagnostic systems for clinical laboratory and point-of-care sectors. The company’s product portfolio encompasses diagnostic tests and instruments that are used to dete …
  • Karyopharm Therapeutics Inc (KPTI):企業の財務・戦略的SWOT分析
    Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • FTS International Inc (FTSI):企業の財務・戦略的SWOT分析
    FTS International Inc (FTSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Lundin Petroleum AB (LUPE):石油・ガス:M&Aディール及び事業提携情報
    Summary Lundin Petroleum AB (Lundin Petroleum) is an independent oil and gas exploration and production company that acquires, explores, develops and produces oil and gas properties in Norway. The company identifies and matures exploration targets, drill exploration wells, appraise discoveries, and …
  • Policolor SA:企業の戦略的SWOT分析
    Policolor SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • The Timken Co (TKR):電力:M&Aディール及び事業提携情報
    Summary The Timken Co (Timken) is an industrial technology company that develops, produces and sells mechanical components. The company offers engineered bearings, mechanical power transmission products, switch gears and electric motors and generators. Timken also offers remanufacture and repair, ma …
  • Ossur hf (OSSR):企業の財務・戦略的SWOT分析
    Ossur hf (OSSR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • genedrive plc (GDR)-製薬・医療分野:企業M&A・提携分析
    Summary genedrive plc (genedrive), formerly Epistem Holdings plc is a molecular diagnostics company. The company focuses on the development and commercialization of simple to use “point of need” system or point of care diagnostics platform for the diagnosis of infectious diseases and use in patient …
  • Toyobo Co., Ltd.:企業の戦略・SWOT・財務分析
    Toyobo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toyobo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • P2P Global Investments PLC (P2P):企業の財務・戦略的SWOT分析
    P2P Global Investments PLC (P2P) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆